Time to initiation of anti-tuberculosis treatment

被引:68
|
作者
Pirkis, JE
Speed, BR
Yung, AP
Dunt, DR
MacIntyre, CR
机构
[1] FAIRFIELD HOSP,FAIRFIELD,VIC 3078,AUSTRALIA
[2] AUSTRALIAN NATL UNIV,NATL CTR EPIDEMIOL & POPULAT HLTH,CANBERRA,ACT 2601,AUSTRALIA
[3] UNIV WESTERN AUSTRALIA,DEPT PUBL HLTH,NEDLANDS,WA 6009,AUSTRALIA
来源
TUBERCLE AND LUNG DISEASE | 1996年 / 77卷 / 05期
关键词
D O I
10.1016/S0962-8479(96)90111-2
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Objective: To examine delay in initiation of treatment for tuberculosis (TB). Design: Delay in the initiation of treatment for 142 notified TB patients was examined by a retrospective record review. Particular attention was given to the periods between (1) onset of symptoms and initiation of treatment, and (2) determination of sputum positivity and initiation of treatment. An expert panel nominated 30 days and 3 days as 'acceptable' periods for (1) and (2), respectively. Results: Only 31% of patients commenced treatment within 30 days of onset of symptoms. This was so for both sputum smear-positive and negative cases, and was not significantly related to the site of infection, referral source, age, gender or ethnicity of the patient. Of patients with smear-positive pulmonary TB, 86% received treatment within 3 days of this result being demonstrated. Those with a delay of greater than 3 days were all investigated by private doctors through private laboratories. Conclusion: There are appreciable delays in initiation of treatment for TB. Measures to combat these unacceptable delays are discussed.
引用
收藏
页码:401 / 406
页数:6
相关论文
共 50 条
  • [31] A metabolic biosignature of early response to anti-tuberculosis treatment
    Mahapatra, Sebabrata
    Hess, Ann M.
    Johnson, John L.
    Eisenach, Kathleen D.
    DeGroote, Mary A.
    Gitta, Phineas
    Joloba, Moses L.
    Kaplan, Gilla
    Walzl, Gerhard
    Boom, W. Henry
    Belisle, John T.
    BMC INFECTIOUS DISEASES, 2014, 14
  • [32] Impact of tobacco smoking on anti-tuberculosis treatment outcomes
    Lesnic, Evelina
    Zlepca, Vasile
    EUROPEAN RESPIRATORY JOURNAL, 2013, 42
  • [33] HEPATOPROTECTIVE EFFECT OF HERBAL REMEDY WITH ANTI-TUBERCULOSIS TREATMENT
    Satayeva, L. G.
    Sagantayeva, S. K. H.
    Garankina, R. U. L.
    VALUE IN HEALTH, 2017, 20 (09) : A798 - A798
  • [34] Anti-tuberculosis treatment for Devic's neuromyelitis optica
    Feng, Yan-qing
    Guo, Ning
    Huang, Fan
    Chen, Xi
    Sun, Qiao-song
    Liu, Jun-xiu
    JOURNAL OF CLINICAL NEUROSCIENCE, 2010, 17 (11) : 1372 - 1377
  • [35] A metabolic biosignature of early response to anti-tuberculosis treatment
    Sebabrata Mahapatra
    Ann M Hess
    John L Johnson
    Kathleen D Eisenach
    Mary A DeGroote
    Phineas Gitta
    Moses L Joloba
    Gilla Kaplan
    Gerhard Walzl
    W Henry Boom
    John T Belisle
    BMC Infectious Diseases, 14
  • [36] Is the Prophylactic Use of Hepatoprotectants Necessary in Anti-Tuberculosis Treatment?
    Xu, Li
    Zhang, Fei
    Xu, Chen
    Liu, Kai-ge
    Wu, Wei
    Tian, Ying-xuan
    CHEMOTHERAPY, 2017, 62 (05) : 269 - 278
  • [37] Delayed response to anti-tuberculosis treatment in a patient on infliximab
    Vlachaki, E
    Psathakis, K
    Tsintiris, K
    Iliopoulos, A
    RESPIRATORY MEDICINE, 2005, 99 (05) : 648 - 652
  • [38] Orbital Myositis as a Paradoxical Reaction to Anti-Tuberculosis Treatment
    Yano, Koichi
    Yokosuka, Kyoko
    Amemiya, Kiyomi
    Sakashita, Kentaro
    Ishida, Takuto
    BALKAN MEDICAL JOURNAL, 2025, 42 (01) : 77 - 78
  • [39] Adherence to anti-tuberculosis treatment in Tigray, Northern Ethiopia
    Kiros, Y. K.
    Teklu, T.
    Desalegn, F.
    Tesfay, M.
    Klinkenberg, E.
    Mulugeta, A.
    PUBLIC HEALTH ACTION, 2014, 4 : S31 - S36
  • [40] Adverse drug reactions reported with anti-tuberculosis treatment
    Tran, T. T.
    Salvo, F.
    Miremont-Salame, G.
    Haramburu, F.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2014, 28 : 93 - 94